Chemogenomic approaches to drug discovery: Commentary

Current Opinion in Chemical Biology

Volumn 5, Issue 4, 2001, Pages 464-470

  Caron, Paul R ^a   Mullican, Michael D ^a   Mashal, Robert D ^a   Wilson, Keith P ^a   Su, Michael S ^a   Murcko, Mark A ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA CONVERTING ENZYME; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; STAUROSPORINE; SYNAPTOPHYSIN;

CHEMICAL GENETICS; DRUG IDENTIFICATION; ENZYME STRUCTURE; GENE MAPPING; GENE STRUCTURE; GENE TARGETING; MULTIGENE FAMILY; MUTAGENESIS; REVIEW; STRUCTURE ANALYSIS;

DRUG DESIGN; GENOME, HUMAN; HUMANS; MUTAGENESIS; PHARMACOGENETICS;

EID: 0035415863     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(00)00229-5     Document Type: Note

References (39)

1. Initial sequencing and analysis of the human genome
2. The sequence of the human genome
3. The role of innovation in drug development
4. Chemical genetics resulting from a passion for synthetic organic chemistry
5. Drug discovery in the next millennium
6. Systematization of research
7. Structure-activity relationship homology (SARAH): A conceptual framework for drug discovery in the genomic era
8. Forecasting roles of combinatorial chemistry in the age of genomically derived drug discovery targets
9. The impact of genomics on drug discovery
10. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase
11. Molecular basis for p38 protein kinase inhibitor specificity
12. A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase
13. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket
14. Structural implications of drug-resistant mutants of HIV-1 protease: High-resolution crystal structures of the mutant protease/substrate analogue complexes
15. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: Insights into the mechanisms of drug resistance
16. + conduction and selectivity
17. Crystal structure of rhodopsin: A G protein-coupled receptor
18. The gating mechanism of the large mechanosensitive channel MscL
19. ATP site-directed competitive and irreversible inhibitors of protein kinases
20. The development and therapeutic potential of protein kinase inhibitors
21. Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine
22. Regulation of transcription by MAP kinase cascades
23. Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme
24. Recent advances on neuronal caspases in development and neurodegeneration
25. The structures of caspases-1, -3, -7 and -8 reveal the basis for substrate and inhibitor selectivity
26. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
27. Virtual screening: An overview
28. Can we learn to distinguish between 'drug-like' and 'nondrug-like' molecules?
29. Designing libraries with CNS activity
30. The properties of known drugs. 1. Molecular frameworks
31. Properties of known drugs. 2. Side chains
32. Structure-based drug design
33. Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins
34. The SHAPES strategy: An NMR-based approach for lead generation in drug discovery
35. NMR-based approaches for lead generation in drug discovery
36. Drug discovery: A historical perspective